Literature DB >> 30481375

Updates in adjuvant systemic therapy for melanoma.

Minyoung Kwak1, Norma E Farrow2, April K S Salama3, Paul J Mosca2, Brent A Hanks3,4, Craig L Slingluff1, Georgia M Beasley2.   

Abstract

There has been a rapid increase in adjuvant therapies approved for treatment following surgical resection of stages III/IV melanoma. We review current indications for adjuvant therapy, which currently includes a heterogenous group of stages III and IV patients with melanoma. We describe several pivotal clinical trials of systemic immune therapies, targeted immune therapies, and adjuvant vaccine strategies. Finally, we discuss the evidence for selecting the most appropriate treatment regimen(s) for the individual patient.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  adjuvant therapy; melanoma

Mesh：

Year:  2018        PMID： 30481375      PMCID： PMC6330126          DOI： 10.1002/jso.25298

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  8 in total

1.  Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2).

Authors:  Kristy Kummerow Broman; Tasha Hughes; Lesly Dossett; James Sun; Dennis Kirichenko; Michael J Carr; Avinash Sharma; Edmund K Bartlett; Amanda A G Nijhuis; John F Thompson; Tina J Hieken; Lisa Kottschade; Jennifer Downs; David E Gyorki; Emma Stahlie; Alexander van Akkooi; David W Ollila; Jill Frank; Yun Song; Giorgos Karakousis; Marc Moncrieff; Jenny Nobes; John Vetto; Dale Han; Jeffrey M Farma; Jeremiah L Deneve; Martin D Fleming; Matthew C Perez; Michael C Lowe; Roger Olofsson Bagge; Jan Mattsson; Ann Y Lee; Russell S Berman; Harvey Chai; Hidde M Kroon; Juri Teras; Roland M Teras; Norma E Farrow; Georgia Beasley; Jane Yuet Ching Hui; Lukas Been; Schelto Kruijff; Youngchul Kim; Syeda Mahrukh Hussnain Naqvi; Amod A Sarnaik; Vernon K Sondak; Jonathan S Zager
Journal:  Cancer       Date:  2021-04-07       Impact factor: 6.921

Review 2.  An evidence-based approach to positive sentinel node disease: should we ever do a completion node dissection?

Authors:  Jennifer S Downs; David E Gyorki
Journal:  Melanoma Manag       Date:  2019-10-18

3.  Lymphangiogenesis-inducing vaccines elicit potent and long-lasting T cell immunity against melanomas.

Authors:  Maria Stella Sasso; Nikolaos Mitrousis; Yue Wang; Priscilla S Briquez; Sylvie Hauert; Jun Ishihara; Jeffrey A Hubbell; Melody A Swartz
Journal:  Sci Adv       Date:  2021-03-24       Impact factor: 14.136

Review 4.  Molecular Biomarkers for Melanoma Screening, Diagnosis and Prognosis: Current State and Future Prospects.

Authors:  Dekker C Deacon; Eric A Smith; Robert L Judson-Torres
Journal:  Front Med (Lausanne)       Date:  2021-04-16

Review 5.  The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges.

Authors:  Henner Stege; Maximilian Haist; Carmen Loquai; Stephan Grabbe; Ulrike Nikfarjam; Michael Schultheis; Jaqueline Heinz; Saskia Pemler
Journal:  Target Oncol       Date:  2021-09-23       Impact factor: 4.493

6.  Spatial biology analysis reveals B cell follicles in secondary lymphoid structures may regulate anti-tumor responses at initial melanoma diagnosis.

Authors:  Aaron D Therien; Georgia M Beasley; Kristen E Rhodin; Norma E Farrow; Douglas S Tyler; David Boczkowski; Rami N Al-Rohil; Eda K Holl; Smita K Nair
Journal:  Front Immunol       Date:  2022-08-15       Impact factor: 8.786

7.  Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection.

Authors:  Kristy K Broman; Deepti Bettampadi; Jaileene Pérez-Morales; James Sun; Dennis Kirichenko; Michael J Carr; Zeynep Eroglu; Ahmad A Tarhini; Nikhil Khushalani; Matthew B Schabath; Amod Sarnaik; Vernon K Sondak; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2021-08-06       Impact factor: 5.344

8.  Overexpression of RACK1 Predicts Poor Prognosis in Melanoma.

Authors:  Congcong Shen; Hui Hua; Lixiong Gu; Shuanglin Cao; Hengji Cai; Xiaodong Yao; Xiaodong Chen
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.